(Q50858431)

24 March 2018

meta-analysis

0 references

title

Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. (English)

1 reference

24 March 2018

0 references

1 reference

Yi Zhou

1

1 reference

24 March 2018

Yang Yuan

2

1 reference

24 March 2018

Rong-Rong Cai

3

1 reference

24 March 2018

Yan Huang

4

1 reference

24 March 2018

Wen-Qing Xia

5

1 reference

24 March 2018

Yue Yang

6

1 reference

24 March 2018

Pin Wang

7

1 reference

24 March 2018

Qiong Wei

8

1 reference

24 March 2018

Shao-Hua Wang

9

1 reference

24 March 2018

language of work or name

English

0 references

publication date

5 July 2013

1 reference

24 March 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

24 March 2018

volume

14

1 reference

24 March 2018

issue

12

1 reference

24 March 2018

page(s)

1575-1584

1 reference

24 March 2018

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

Are statins diabetogenic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810210

10.1517/14656566.2013.810210

21 January 2018

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018